There has been recent demonstration that elotuzumab and anti-PD-1 mAb in combination lead to antitumor efficacy enhancement in the myeloma mouse model in the study published by Bezman et al. In these mouse models, combination treatment with elotuzumab and anti–PD-1 promoted tumor-infiltrating NK and CD8+ T-cell activation, as well as increased intra-tumoral cytokine and chemokine release. The gene discussed is PDCD1; the disease is neoplasm.